Drugs online research references
Reprod Freedom News. 1996 Jul 12;5(12):7.
FDA finds emergency postcoital contraception safe and effective.
[No authors listed]
PIP: During a 1996 hearing, the US Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee reached the unanimous conclusion that certain oral contraceptives (OCs) are safe and effective for use in an emergency postcoital regimen. Because such a regimen reduces the risk of unintended pregnancies by about 75%, widespread access to emergency contraception in the US could prevent as many as 1.7 million pregnancies and 1 million abortions each year. The six brands of OCs manufactured in the US which contain the necessary chemical compound are Ovral, Lo/Ovral, Nordette, Triphasil, Levlen, and Tri-Levlen. For Ovral, the regimen involves taking two pills within 72 hours of unprotected intercourse followed 12 hours later by another two pills. The other OCs require a dosage of four pills each time. When using Levlen and Tri-Levlen, the yellow pills are the only ones which are effective. Publication of the FDA's support should spur pharmaceutical companies to petition the agency for virtually automatic approval of this use of OCs. Drug manufacturers have failed to take this action to date because of the fear of the opposition of antiabortion groups and of product liability suits. Detailed information on various types of emergency contraception and on physicians who provide this service can be obtained from the Reproductive Health Technologies Project hotline (1-800-584-9911).
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12291423&dopt=Abstract
word match triphasil online literature
Network. 1996 Summer;16(4):14-7.
OCs provide emergency contraception option.
Blaney CL.
PIP: Administered in high doses, certain types of oral contraceptives (OCs) can be used after unprotected intercourse to prevent pregnancy. This regimen is safe and 75% effective; it appears to alter the uterine lining, thereby preventing implantation. The usual regimen consists of a dose of at least 100 mcg of ethinyl estradiol and 0.5 mg of levonorgestrel taken within 72 hours of unprotected sex and repeated 12 hours later; alternatively, 0.75 mg of levonorgestrel administered within 48 hours and repeated 12 hours later can be used. The US Food and Drug Administration has identified the following OCs as appropriate for use as emergency contraception: Wyeth's Ovral, Nordette, Lo/Ovral, or Triphasil and Berlex Laboratories' Levlen or Tri-Levlen. Despite the high doses required, these OCs can be taken safely for emergency purposes even by women with contraindications to regular OC use. A single dose of 600 mg of RU-486 or insertion within 5 days of a copper-bearing IUD represent two other approaches. In the US, more widespread use of emergency contraception has been hindered by equation of the method with abortion, the misperception that pills must be taken the morning after unprotected sex, lack of staff training, lack of consumer awareness of its availability and source, concerns women will substitute the method for consistent contraceptive use, and the lack of any formulation specifically marketed for this purpose. On the other hand, the method is used widely in parts of Africa to protect women from the risks of illegal abortion. The Consortium for Emergency Contraception plans to work with industry to produce an inexpensive emergency contraceptive that will be introduced in up to 15 developing countries over the next 5 years.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12291586&dopt=Abstract
word match triphasil online literature
Contracept Technol Update. 1984 Mar;5(3):35-6.
Estrogen, progesterone dosage varies in new oral contraceptive.
[No authors listed]
PIP: Wyeth Laboratories is seeking US Food and Drug Administration approval to market an oral contraceptive (OC), Triphasil, that delivers varying doses of estrogen and progesterone during each part of the menstrual cycle. The pill is already being marketed in Germany and the United Kingdom under the name Trinordiol. Triphasil provides an increased estrogen dosage at midcycle (30 mcg at days 1-6, 40 mcg at days 7-11, and 30 mcg at days 12-21) and an increased progesterone dose as the cycle progresses (50 mcg at days 1-6, 75 mcg at days 7-11, and 125 mcg at days 12-21). The low progesterone dose during the early part of the cycle is thought to be beneficial because the progesterone component of OCs has been linked to increased cholesterol levels. Wyeth's studies of more than 3546 women demonstrated high acceptability and an unplanned pregnancy rate of 0.33 pregnancies/100 women years. No cases of thromboembolism or other serious complications were noted in more than 35,000 cycles. Change in vaginal bleeding, which occurred in 2.9% of the women, was the most common medical reason for discontinuation. 78% of 109 women who conceived after discontinuing Triphasil became pregnant within 6 months. Triphasil is considered to be a suitable contraceptive for any woman in whom OCs are not contraindicated. However, its low steroid dose may not be sufficient to control conditions such as irregular bleeding, excessive bleeding, or dysfunctional bleeding.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12312849&dopt=Abstract
word match triphasil online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||